34127-22-5

Basic information

• Product Name: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE
• Synonyms: 3,6-Dichloropyridazine-4-carboxylic acid ethyl ester;ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE;4-Pyridazinecarboxylic acid, 3,6-dichloro-, ethyl ester
• CAS NO: 34127-22-5
• Molecular Formula: C₇H₆Cl₂N₂O₂
• Molecular Weight: 221.04074
• Mol File: 34127-22-5.mol

Chemical Properties

• Boiling Point: 364.2±37.0 °C(Predicted)
• Appearance: /
• Density: 1.433±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -3.52±0.10(Predicted)
• CAS DataBase Reference: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE(34127-22-5)
• EPA Substance Registry System: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE(34127-22-5)

Safety Data

• Hazardous Substances Data: 34127-22-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE is used as a precursor in the production of pesticides and other agrochemicals. Its chemical properties make it suitable for the creation of compounds that can effectively control pests and diseases in agriculture.
As a Hazardous Chemical:
ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE is considered a hazardous chemical due to its potential health and environmental risks. It requires proper handling, storage, and disposal procedures to minimize any adverse effects on human health and the environment. This includes the use of personal protective equipment, secure storage conditions, and adherence to safety regulations during its production and use.

Upstream product

• 64-17-5 ethanol 
• 51149-08-7 3,6-dichloropyridazin-4-carboxylic acid 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 5754-18-7 3,6-dihydroxy-4-methylpyridazine 

Downstream Products

• 151322-61-1 ethyl 3-biphenyl-4-yl>methyl>amino>-6-chloropyridazine-4-carboxylate 
• 157361-64-3 3-{Butyl-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-6-chloro-pyridazine-4-carboxylic acid ethyl ester 
• 151322-81-5 ethyl 3-biphenyl-4-yl>methyl>amino>pyridazine-4-carboxylate 
• 27427-66-3 3,6-dichloropyridazine-4-carboxamide 
• 34121-92-1 3-chloro-6-methoxy-pyridazine-4-carboxylic acid amide 
• 34127-26-9 6-chloro-3-methoxy-pyridazine-4-carboxylic acid amide 
• 1161847-32-0 ethyl 3-amino-6-chloropyridazine-4-carboxylate 

Relevant articles and documents

GSK-3 INHIBITORS

The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON

The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS

Novel compounds are provided which are 1 1 -beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxys

QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE

Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

PYRIDAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS

The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3, each R1 group has any of the meanings defined in the description, Ra is halogeno or (1-6C)alkoxy, Rb is halogeno or (1-6C)alkoxy, and Rc is hydrogen, halogeno, (1-8C)alkyl or (1-6C)alkoxy, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists

A series of pyridines and other six-membered ring heterocycles connected to a biphenyltetrazole with a-CH2-NR'-link (1) were discovered to be potent angiotensin II antagonists.In the pyrimidine carboxylic acid series (W = CR, X = N, Y = CH, Z = COOH), compounds with an alkyl group (R') on the exocyclic nitrogen were much more potent than compounds with an alkyl group (R) on the heterocyclic ring.The corresponding pyridine, pyridazine, pyrazine, and 1,2,4-triazine carboxylic acids also showed potent in vitro angiotensin II antagonism.The pyridine (W, X, Y = CH, Z = COOH, R' = n-C3H7) demonstrated potent in vitro activity (pA2 = 10.10, rabbit aorta, and Ki = 0.61 nM, receptor binding in rat liver) as well as exceptional oral antihypertensive activity and bioavailability.Any nonacidic replacement for the carboxylic acid was detrimental for activity.